36 , 37 Although inconclusive, the ADVANCE study (a phase 4 randomized clinical trial) showed a trend toward vascular calcification progression attenuation among subjects receiving low doses of active vitamin D and cinacalcet versus flexible doses of vitamin D to control SHPT. 38 Overall, a small but not significant reduction in coronary artery calcification (CAC) progression was noted.
← all excerpts
Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
1
—
—